JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoan Lamarche
Raymond Cartier
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcheix, B.
Right arrow Articles by Cartier, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marcheix, B.
Right arrow Articles by Cartier, R.
Related Collections
Right arrow Valve disease
Right arrowRelated Article

J Thorac Cardiovasc Surg 2007;134:1150-1156
© 2007 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis

Bertrand Marcheix, MD, MSca, Yoan Lamarche, MD, MSca, Colin Berry, MD, PhDb,2, Anita Asgar, MDb, Jean-Claude Laborde, MDc,1, Arsène Basmadjian, MD, MScb, Anique Ducharme, MD, MScd, André Denault, MDe, Raoul Bonan, MDb,1, Raymond Cartier, MDa,*

a Department of Cardiovascular Surgery, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada
b Department of Cardiology, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada
e Department of Anesthesiology, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada
c Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France
d Department of Anesthesiology, Montreal Heart Institute, Montreal, Quebec, Canada.

Received for publication February 9, 2007; revisions received July 3, 2007; accepted for publication July 10, 2007.

* Address for reprints: Raymond Cartier, MD, Department of Cardiovascular Surgery, Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada. (Email: rc2910{at}aol.com).


   Abstract
Top
 Abstract
Introduction
 Patients and Methods
 Results
 Discussion
 Conclusions
 References
 
Objectives: Aortic stenosis is one of the most common forms of acquired valvular heart disease in adults, and the proportion of patients unsuitable for conventional surgery is increasing. Consequently, the development of new less-invasive techniques to treat severe aortic stenosis is crucially important. Current experience in percutaneous aortic valve replacement is limited to a few groups, and the search for an optimal technique continues. We report our experience with retrograde endovascular bioprosthesis implantation with brief cardiopulmonary bypass support in high-risk older patients.

Methods: The CoreValve pericardial bioprosthesis (CoreValve, Inc, Paris, France) is sutured on a nitinol frame and delivered in a 21F catheter. All procedures were performed under femoro–femoral cardiopulmonary bypass support consisting of an aortic balloon valvuloplasty followed by prosthesis deployment within the aortic annulus under fluoroscopy. Ten high-risk surgical patients underwent percutaneous valve replacement.

Results: Immediate improvement in aortic valve function was observed in all patients. The aortic valve area increased from 0.57 ± 0.19 to 1.2 ± 0.35 cm2 (P = .00001), the mean transaortic valve gradient decreased from 51 ± 19 to 11 ± 3 mm Hg (P < .001). The 30-day mortality was 20%: one patient died 5 days after the procedure of a massive ischemic stroke and 1 patient died at 20 days of a hemorrhagic stroke. The median New York Heart Association functional class improved from III to II (P = .01).

Conclusions: Aortic valve replacement with the CoreValve bioprosthesis can be performed with favorable early technical results in high-risk patients. However, the morbidity and short-term mortality of such procedures remain significant.

Abbreviations and Acronyms AS = aortic stenosis; AVR = aortic valve replacement; PAVR = percutaneous aortic valve replacement; TEE = transesophageal echocardiography


   Introduction
Top
 Abstract
 Introduction
Patients and Methods
 Results
 Discussion
 Conclusions
 References
 

Figure 1
Dr Cartier


Aortic stenosis (AS) is one of the most common forms of acquired valvular heart disease in adults.1,2Go Open chest aortic valve replacement (AVR) is the "gold standard," improving survival and alleviating symptoms.2-4Go Nevertheless, the surgical approach is associated with substantial operative mortality rates in high-risk patients. Consequently, almost one third of patients with severe AS are not offered surgery owing to a combination of reasons such as advanced age, impaired left ventricular function, redo procedure, or multiple comorbidities.5Go The prevalence of AS increases with age,2Go and as longevity within the general population is increasing, the proportion of AS patients with contraindications for surgery is also expected to increase. Consequently, a less invasive and safer alternative to surgical aortic valve replacement for these patients is being increasingly recognized.

Balloon aortic valvuloplasty, originally described in the 1980s,6Go was the first alternative to surgical therapy. However, despite high rates of procedural success, restenosis led to disappointing results in the longer term in adult patients and has been abandoned.7Go Recent success with percutaneous pulmonary valve implantation8Go supports the possibility of percutaneous aortic valve replacement (PAVR). So far, early experience with this technique in humans is limited to a few devices.9-11Go

The optimal approach for PAVR continues to be investigated and several questions require clarification: method of approach (transaortic vs transapical), delivery catheter size, and circulatory support (cardiopulmonary bypass, temporary left ventricular assistance, or rapid ventricular pacing).

We report our early experience with a new endovascular technology allowing retrograde implantation with brief peripheral cardiopulmonary bypass support.


   Patients and Methods
Top
 Abstract
 Introduction
 Patients and Methods
Results
 Discussion
 Conclusions
 References
 
High-risk patients with severe symptomatic AS were referred for a percutaneous procedure because of a high or prohibitive risk with conventional surgery. The procedures were approved by the Therapeutic Products Directorate, Department of Health and Welfare, Ottawa, Canada, for compassionate clinical use in patients unsuitable for surgery. Informed written consent was obtained.

We reviewed our initial 9-month experience from December 2005 to August 2006. Patients underwent transthoracic echocardiography, iliofemoral contrast angiography, and coronary angiography. Clinical evaluation and echocardiograms (VIVID7; GE Healthcare, Milwaukee, Wis) were obtained before the procedure, within 24 hours of the procedure, at day 10, and at 1 month after the procedure.

Prosthetic Valve System
The CoreValve aortic valve prosthesis (CoreValve, Inc, Paris, France) consists of a single-size bioprosthetic valve made of porcine pericardial tissue, which is mounted and sutured in a self-expanding hourglass-shaped 55-mm length nitinol frame (Figure 1, A). The lower part of the frame has a high radial force to overcome valvular calcification and prevent recoil, and it serves to anchor the prosthesis in the annulus. The mid part of the frame is constrained to avoid coronary ostia and carries the valve leaflets, whereas the upper part expands in the proximal ascending aorta to ensure stability and central alignment of the prosthesis. The actual valve inner diameter is 22 mm. At the time of the procedure, the nitinol valve is chilled in cold saline and retracted into the 21F delivery catheter by a compression and loading system.


Figure 1
View larger version (108K):
[in this window]
[in a new window]

  		Figure 1. CoreValve percutaneous aortic prosthesis (A). Perioperative x-ray imaging demonstrating 23-mm balloon dilatation of the stenotic aortic valve (B). Retrograde delivery catheter advancement toward the aortic arch and deployment of the prosthesis (C–E). A perioperative angiogram demonstrated excellent position and function of the bioprosthesis. The left and right coronary ostia are patent. There is no evidence of intraprosthetic or periprosthetic insufficiency (F).

 
Procedure
The procedures were conducted in a sterile cardiologic interventional suite (Allura X per FD 10; Philips, Eindhoven, The Netherlands) in accordance with the World Health Organization’s recommendations on air handling in surgical suites. The infrainguinal iliofemoral arterial junction was surgically exposed bilaterally. Through either right radial or brachial artery access, angiography of the ascending aorta was performed via a right anterior oblique view. After this, a straight Terumo Glidewire (Terumo Medical Corp, Somerset, NJ) was advanced through the iliofemoral arteriotomy and directed across the aortic valve with an Amplatz AL1 or AL2 diagnostic catheter (Cordis Corp, Miami, Fla). This wire was then exchanged for a 0.035-inch Amplatz Extra Stiff (Boston Scientific, Natick, Mass) guidewire to maintain a secure wire position within the left ventricle. The patient was heparinized (3 mg/kg), and then venous (21F-23F) and arterial femoral canulas (17F or 19F) were inserted, permitting femoro–femoral cardiopulmonary bypass. Transesophageal echocardiography (TEE) and fluoroscopy were used to optimize venous cannula positioning in the right atrium during cardiopulmonary bypass. Valvuloplasty with a 23F balloon catheter (Numed, Hopkinton, NY) was first performed to optimize the valve area (Figure 1, B). After this, a delivery catheter was advanced under fluoroscopic guidance (Figure 1, C and D). The prosthesis was positioned with its distal third adjacent to the calcified native leaflets under fluoroscopy. The prosthesis was deployed by careful retraction of the delivery sheath (Figure 1, E and F). Angiograms and TEE were systematically performed to verify the position and competent function of the prosthesis, as well as the patency of the coronary ostia. If significant periprosthetic leaks occurred immediately after PAVR, intraprosthetic balloon dilatation was performed to achieve an optimal seal with the aortic annulus. Cardiopumonary bypass was then progressively weaned, followed by removal of the sheath and cannulas and reversal of heparin.

Preoperative and Postoperative Care
All patients received either vancomycin or cefazolin intravenously (1 g) immediately before the procedure. Antibiotic prophylaxis was systematicaly continued for 48 hours. Combination therapy with aspirin (325 mg) and clopidogrel (300 mg loading dose followed by 75 mg daily maintenance dose) was started preoperatively and given after the procedure for 3 months. Aspirin (80 mg daily) monotherapy was then continued indefinitely. Low-dose subcutaneous heparin (5000 IU twice daily) was administered for thromboprophylaxis until patients were ambulatory.

Statistical Analyses
Continuous normally distributed variables are expressed as mean ± SD and analyzed by the paired Student t tests or analysis of variance. Continuous non-normally distributed data are expressed as median (interquartile range) and analyzed with a Wilcoxon or Kruskal–Wallis test Categorical data were analyzed by a Pearson {chi}2 test. All statistical analyses were undertaken with StataCorp version 7 software (StataCorp, College Station, Tex). Adjustments were not made for multiple testing.


   Results
Top
 Abstract
 Introduction
 Patients and Methods
 Results
Discussion
 Conclusions
 References
 
Patients
PAVR with full cardiopulmonary bypass was performed in 10 patients with severe symptomatic AS between December 2005 and August 2006. Patients’ pre-procedural characteristics are shown in Table 1. Three patients were in New York Heart Association class IV and the others were in class III (n = 7). Nine patients were 80 years old or more. All patients had been deemed by at least two cardiothoracic surgeons to be at prohibitively high surgical risk for conventional open chest AVR. The predicted mortality rates if conventional procedures were performed were 22.9% ± 15.3% and 32% (21%–40%), respectively, according to the Parsonnet and logistic EuroSCORE preoperative risk estimation scores. Specific contraindications for surgery are listed in Table 2.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Preoperative characteristics of 10 patients
 

View this table:
[in this window]
[in a new window]

  		TABLE 2 Specific contraindications for surgery
 
Procedures
Valvuloplasty, delivery catheter positioning, and bioprosthetic valve deployment were successful in all patients. No patient died during the procedure and no patient required conversion to a conventional open chest procedure (Table 3). Mean procedure time was 3.2 ± 0.9 hours.


View this table:
[in this window]
[in a new window]

  		TABLE 3 Procedures and postoperative course
 
Positioning of the venous cannula in the right atrium and the efficiency of the venous return were assessed with TEE and fluoroscopy. Vacuum-assisted venous return was used if necessary (20–40 mm Hg). Median cardiopulmonary bypass time was 28 minutes (range: 19–83 minutes). One patient underwent a combined procedure with angioplasty and stent implantation for a tight stenosis of the left anterior descending artery and AVR. Two patients required percutaneous angioplasty of the common iliac artery to allow progression of the sheath. In one 85-year-old patient (patient 7), after percutaneous angioplasty and successful placement of the prosthesis, periprocedural TEE identified a large atherosclerotic plaque in the left ventricular outflow tract. The debris was retrieved with an endovascular bioptome and ex vivo analysis confirmed the tissue to be vascular, most likely iliac artery tissue displaced by delivery catheter advancement. The procedure was complicated by a hemopericardium (owing to the bioptome manipulation) that required emergency pericardiocentesis. The patient subsequently experienced hemorrhagic shock in the early postoperative period, and surgical exploration of the abdomen identified hepatic trauma and intraperitoneal hemorrhage.

Postoperative Course
Mean mechanical ventilation time was 7.8 ± 4.7 hours. All patients had mild transient elevation of creatine kinase MB and troponin T as indicated in Table 3. The operative (30-day) mortality was 20% and hospital mortality was 30% (including operative mortality). Postoperative complications are shown in Table 3. Patient 7 died on the fifth postoperative day after a massive hemispheric ischemic stroke. One patient had a postoperative ophthalmoplegia related to an embolic event. Three other patients had transient confusion without computed tomographic evidence of cerebral embolization. Two patients required pacemaker implantation because of persistent atrioventricular block. Two patients had transient nonsustained atrial fibrillation. Vascular access complications were encountered in 5 patients: 1 had a hematoma, 2 had lymphoceles, and 2 required femoral arterial reconstructions (patch angioplasty). Femoral wound infection was encountered in 1 patient with bilateral lymphoceles. Two patients required reoperation, 1 (patient 7) because of intra-abdominal bleeding related to pericardial (and inadvertent hepatic) puncture (patient 7) and another for an infected inguinal lymphocele. The mean intensive care unit stay was 4.6 ± 2.2 days and the mean hospital stay was 15 ± 12 days.

Perioperative Prosthesis Evaluation
The prosthesis was assessed at the end of each procedure by utilizing TEE and angiography. Immediate improvement in aortic valve function was observed in all patients. The aortic valve area increased from 0.57 ± 0.19 to 1.2 ± 0.35 cm2 (P = .00001) (Figure 2, A) and the mean transaortic valve gradient decreased from 51 ± 19 to 11 ± 3 mm Hg (P < .001) (Figure 2, B). Five patients had mild intraprosthetic insufficiency (<1) and 8 patients had a mild-to-moderate periprosthetic leak (grade 1/4 [n = 7] or 2/4 [n = 1]; Figure 2, C). Perivalvular leak remained stable over the first month.


Figure 2
View larger version (26K):
[in this window]
[in a new window]

  		Figure 2. Improvements in the aortic valve (AV) area (A) and mean transaortic gradient after endovascular AVR (B). Aortic valve regurgitation remained mild (≤ grade 2, and ≤ grade 1 in most) immediately after AVR and during follow-up (C). Improvement in New York Heart Association (NYHA) functional class (D). Each curve represents the data for 1 patient. PAVR, Percutaneous aortic valve replacement; AI, aortic insufficiency; SD, standard deviation.

 
Follow-up (1 Month)
One patient had an intracerebral hemorrhage on day 20 and died. New York Heart Association class improved by at least one point in all surviving patients (Figure 2, D). No patient had any hemolysis or evidence of endocarditis, and no patient required any reintervention for valve dysfunction or any hospital readmission. The 3-month mortality was 30% and our first patient remains well more than 16 months after the procedure. The 3-month mortality was 30% and our first patient remains well more than 16 months after the procedure.

Postmortem Prosthesis Assessment
An autopsy was performed in the patient who died on day 5 (patient 7). Postmortem assessment confirmed good prosthetic valve position and function and found no evidence of any device-related complication. The coronary ostia were patent.


   Discussion
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
Conclusions
 References
 
We report the initial Montreal Heart Institute experience with endovascular implantation of a self-expanding aortic valve prosthesis. We have confirmed that implantation of the prosthesis is feasible, leading to an immediate increase in the valve surface area and a decrease in the transaortic mean gradient. Although every patient had a minor degree of aortic regurgitation, it remained mild to moderate (≤ grade 2 and ≤ grade 1 in most) in all cases. Short-term follow-up in survivors confirmed that these initial results were maintained. None of the patients had problems as a result of unstable coronary artery disease during follow-up. These results confirm the potential for safe and effective PAVR.

Our approach differs from the Cribier–Edwards LifeSciences system in several important ways. By contrast with this latter balloon-expandable stent prosthesis,12,13Go the device used in this series is a self-expanding aortic valve prosthesis designed for retrograde implantation via the arterial iliofemoral arteries. Whereas animal studies have shown that the balloon-expandable prosthesis requires exact device positioning to avoid device embolization,14Go the longer profile and self-expandable properties of nitinol could enhance the stability once deployed.15Go Even though nitinol devices could be susceptible to fracture with time, the same self-expandable technology is commonly used in thoracic aortic stent grafts and has shown good midterm results.16Go After device deployment, intraprosthetic balloon expansion can also be performed to minimize periprosthetic regurgitation but is seldom required.

Mild-to-severe paravalvular aortic regurgitation has been observed in most patients who have undergone percutaneous implantation of the balloon-expandable valve prosthesis.17Go One possible advantage of a self-expanding prosthesis is the potential for continued expansion over time, which may in turn reduce paravalvular leaks after implantation.15Go

One theoretical advantage of the antegrade approach is a lower risk of atheroma embolism during delivery catheter advancement through an atheromatous aorta. Nevertheless, the need for transseptal puncture, unavoidable traction on the anterior mitral valve leaflet inducing potentially severe mitral regurgitation, and hemodynamic instability constitute the main drawbacks of this approach.15,18Go Emerging advances in percutaneous procedures include reduced delivery catheter size (ie, 18F delivery system) and alternative approaches (retrograde subclavian or transapical approaches), which may reduce the risk of implantation failure in patients with severe peripheral vascular disease. These new approaches may limit the risk of femoral access site complication.

The relatively brief cardiopulmonary bypass times in this series were sufficient to unload the left heart cavities, ensure hemodynamic stability, and secure the release of the prosthesis in the correct position. Circulatory support may represents a safer alternative to brief rapid cardiac pacing (200–220 beats/min) in patients with severe AS and left ventricular hypertrophy inasmuch as low cardiac output may lead to myocardial ischemia and subsequent hemodynamic instability. Therefore, this was chosen as our method of choice for the beginning of our experience with endovascular replacement of the aortic valve.

The mortality rate observed in our series was similar to that which was predicted using the Parsonnet and EuroSCOREs (20% vs 23%–24%). Three patients were not candidates for surgery and the others were deemed to be very poor candidates for conventional surgery. Two had severe lung disease prohibiting any kind of thoracic exploration and 1 had severe kyphoscoliosis making a classic operative approach impossible. Other scoring systems may help to obtain a better stratification and uniform preoperative risk reporting for endovascular aortic replacement in the future.19Go

The high 1-month mortality was associated with neurologic complications in 2 patients. These complications could possibly be prevented by alternate vascular access in patients with peripheral vascular disease. However, the hemorrhagic stroke at 20 days can be related to the anticoagulation regimen; this was adjusted for the following patients. These comorbidities and the complex postprocedural support needed for these patients before discharge are reflected by a prolonged hospital stay. Long-term follow-up of our patients is ongoing. Immediate improvements of the aortic valve surface area were observed in all patients, device-related complications did not occur, and New York Heart Association functional class improved in all patients, despite their comorbidities.

As reported in aortic endovascular interventions, the main risks for this type of procedure are also embolic stroke and technical problems related to peripheral vascular disease.20Go The significant length of hospital stay in our patients indicates their complex postprocedural supportive needs before discharge.


   Conclusions
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 Conclusions
References
 
Endovascular AVR with a self-expandable bioprosthesis can be performed with favorable immediate results in a cohort of older and high-risk surgical patients. However, the short-term mortality of these patients remains high, most likely due to significant comorbidity. Notably, neurovascular complications are an important postprocedural complication. Prospective studies involving larger numbers of high-risk surgical patients are required to evaluate the potential utility of this emerging and promising technology.


   Footnotes
 
1 Drs Bonan and Laborde are consultants to CoreValve, Inc, Paris, France. Back

2 Dr Berry was supported by a British Heart Foundation International Fellowship. Back


   References
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 Conclusions
 References
 

  1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-1243.[Abstract/Free Full Text]
  2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-1011.[Medline]
  3. Kvidal P, Bergstrom R, Horte LG, Stahle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 2000;35:747-756.[Abstract/Free Full Text]
  4. Schwarz F, Baumann P, Manthey J, Hoffmann M, Schuler G, Mehmel HC, et al. The effect of aortic valve replacement on survival. Circulation 1982;66:1105-1110.[Abstract/Free Full Text]
  5. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?. Eur Heart J 2005;26:2714-2720.[Abstract/Free Full Text]
  6. Cribier A, Saoudi N, Berland J, Savin T, Rocha P, Letac B. Percutaneous trans-luminal valvuloplasty of acquired aortic-stenosis in elderly patients—alternative to valve-replacement. Lancet 1986;1:63-67.[Medline]
  7. Eltchaninoff H, Cribier A, Tron C, Anselme F, Koning R, Soyer R, et al. Balloon aortic valvuloplasty in elderly patients at high-risk for surgery, or inoperable—immediate and mid-term results. Eur Heart J 1995;16:1079-1084.[Abstract/Free Full Text]
  8. Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, Bonnet D, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403-1405.[Medline]
  9. Berry C, Lamarche Y, Laborde JC, Cartier R, Denault A, Basmadjian A, et al. First case of combined percutaneous aortic valve replacement and coronary artery revascularisation. EuroIntervention 2006;2:257-261.
  10. Grube E, Laborde JC, Zickmann B, Gerckens U, Felderhoff T, Sauren B, et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve. Catheter Cardiovasc Interv 2005;66:465-469.[Medline]
  11. Lamarche Y, Berry C, Cartier R, Denault A, Basmadjian A, Laborde JC, et al. First North American implantation of the CoreValve percutaneous aortic valve. Ann Thorac Surg 2007;83:284-287.[Abstract/Free Full Text]
  12. Lichtenstein S, Cheung A, Ye J, Thompson CR, Carere RG, Pasupati S, et al. Transapical transcatheter aortic valve implantation in humans. Initial clinical experience. Circulation 2006;114:591-596.[Abstract/Free Full Text]
  13. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006;113:842-850.[Abstract/Free Full Text]
  14. Boudjemline Y, Bunhoeffer D. Steps toward percutaneous aortic valve replacement. Circulation 2002;105:775-778.[Abstract/Free Full Text]
  15. Laborde JC, Borenstein N, Behr L, Farah B, Fajadet J. Percutaneous implantation of an aortic valve prosthesis. Catheter Cardiovasc Interv 2005;65:171-174.[Medline]
  16. Sunder-Plassmann L, Scharrer-Pamler R, Liewald F, Kapfer X, Gorich J, Orend KH. Endovascular exclusion of thoracic aortic aneurysms: mid-term results of elective treatment and in contained rupture. J Card Surg 2003;18:367-374.[Medline]
  17. Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 2004;43:698-703.[Abstract/Free Full Text]
  18. Webb JG, Munt B, Makkar RR, Naqvi TZ, Dang N. Percutaneous stent-mounted valve for treatment of aortic or pulmonary valve disease. Catheter Cardiovasc Interv 2004;63:89-93.[Medline]
  19. Hannan E, Wu C, Bennett EV, Carlson RE, Culliford AT, Gold JP, et al. Risk index for predicting in-hospital mortality for cardiac valve surgery. Ann Thorac Surg 2007;83:921-930.[Abstract/Free Full Text]
  20. Berry C, Cartier R, Bonan R. Fatal ischemic stroke related to non-permissive peripheral artery access for percutaneous aortic valve replacement. Catheter Cardiovasc Interv 2007;69:56-63.[Medline]

Related Article

Percutaneous aortic valve replacement with the CoreValve bioprosthesis
Rachid Zegdi, Paul Achouh, and Jean-Noël Fabiani
J. Thorac. Cardiovasc. Surg. 2008 135: 1407-1408. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Eur J Cardiothorac SurgHome page
R. Lange, S. Bleiziffer, N. Piazza, D. Mazzitelli, A. Hutter, P. Tassani-Prell, J.-C. Laborde, and R. Bauernschmitt
Incidence and treatment of procedural cardiovascular complications associated with trans-arterial and trans-apical interventional aortic valve implantation in 412 consecutive patients
Eur J Cardiothorac Surg, November 1, 2011; 40(5): 1105 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
J. M. Rubin, P. Avanzas, R. del Valle, A. Renilla, E. Rios, D. Calvo, I. Lozano, I. Anguera, B. Diaz-Molina, A. Cequier, et al.
Atrioventricular Conduction Disturbance Characterization in Transcatheter Aortic Valve Implantation With the CoreValve Prosthesis
Circ Cardiovasc Interv, June 1, 2011; 4(3): 280 - 286.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Modine, J. F. Obadia, E. Choukroun, G. Rioufoul, A. Sudre, J. C. Laborde, and P. Leprince
Transcutaneous aortic valve implantation using the axillary/subclavian access: Feasibility and early clinical outcomes
J. Thorac. Cardiovasc. Surg., February 1, 2011; 141(2): 487 - 491.e1.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Tamburino, D. Capodanno, A. Ramondo, A. S. Petronio, F. Ettori, G. Santoro, S. Klugmann, F. Bedogni, F. Maisano, A. Marzocchi, et al.
Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis
Circulation, January 25, 2011; 123(3): 299 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
S. Geisbusch, S. Bleiziffer, D. Mazzitelli, H. Ruge, R. Bauernschmitt, and R. Lange
Incidence and Management of CoreValve Dislocation During Transcatheter Aortic Valve Implantation
Circ Cardiovasc Interv, December 1, 2010; 3(6): 531 - 536.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. Bruschi, P. Fratto, F. De Marco, J. Oreglia, P. Colombo, L. Botta, A. Cannata, A. Moreo, B. De Chiara, F. Lullo, et al.
The trans-subclavian retrograde approach for transcatheter aortic valve replacement: Single-center experience
J. Thorac. Cardiovasc. Surg., October 1, 2010; 140(4): 911 - 915.e2.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. R. Coeytaux, J. W. Williams Jr., R. N. Gray, and A. Wang
Percutaneous Heart Valve Replacement for Aortic Stenosis: State of the Evidence
Ann Intern Med, September 7, 2010; 153(5): 314 - 324.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. D. Yan, C. Cao, J. Martens-Nielsen, R. Padang, M. Ng, M. P. Vallely, and P. G. Bannon
Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review
J. Thorac. Cardiovasc. Surg., June 1, 2010; 139(6): 1519 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
S. Bleiziffer, H. Ruge, J. Horer, A. Hutter, S. Geisbusch, G. Brockmann, D. Mazzitelli, R. Bauernschmitt, and R. Lange
Predictors for New-Onset Complete Heart Block After Transcatheter Aortic Valve Implantation
J. Am. Coll. Cardiol. Intv., May 1, 2010; 3(5): 524 - 530.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Bleiziffer, H. Ruge, D. Mazzitelli, A. Hutter, A. Opitz, R. Bauernschmitt, and R. Lange
Survival after transapical and transfemoral aortic valve implantation: Talking about two different patient populations
J. Thorac. Cardiovasc. Surg., November 1, 2009; 138(5): 1073 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Salizzoni, P. Bajona, K. J. Zehr, W. D. Anderson, S. Vandenberghe, and G. Speziali
Transapical off-pump removal of the native aortic valve: a proof-of-concept animal study.
J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 468 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Aregger, P. Wenaweser, G. J. Hellige, A. Kadner, T. Carrel, S. Windecker, and F. J. Frey
Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2175 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. H. Rahimtoola
The Year in Valvular Heart Disease
J. Am. Coll. Cardiol., May 19, 2009; 53(20): 1894 - 1908.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Zegdi, G. Sleilaty, A. Lafont, and J.-N. Fabiani
Reply
J. Am. Coll. Cardiol., January 13, 2009; 53(2): 219 - 220.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Zierer, G. Wimmer-Greinecker, S. Martens, A. Moritz, and M. Doss
The transapical approach for aortic valve implantation.
J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 948 - 953.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Bottio
The present and the future in aortic stenosis management: are there factors that might preclude surgery?
J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 538 - 539.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. Zegdi, P. Achouh, and J.-N. Fabiani
Percutaneous aortic valve replacement with the CoreValve bioprosthesis.
J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1407 - 1408.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoan Lamarche
Raymond Cartier
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcheix, B.
Right arrow Articles by Cartier, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marcheix, B.
Right arrow Articles by Cartier, R.
Related Collections
Right arrow Valve disease
Right arrowRelated Article

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS